Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics | Zendy

Timothy P. Cripe | Zendy; Brian Hutzen | Zendy; Mark A. Currier | Zendy; ChunYu Chen | Zendy; Andrea M. Glaspell | Zendy; Grace C. Sullivan | Zendy; Julia M. Hurley | Zendy; Mackenzie R. Deighen | Zendy; Akila S. Venkataramany | Zendy; Xiaokui Mo | Zendy; Joseph Stanek | Zendy; Anthony R. Miller | Zendy; Saranga Wijeratne | Zendy; Vincent Magrini | Zendy; Elaine R. Mardis | Zendy; Jerry R. Mendell | Zendy; Dawn S. Chandler | Zendy; Pin-Yi Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics

Author(s) -

Timothy P. Cripe,

Brian Hutzen,

Mark A. Currier,

ChunYu Chen,

Andrea M. Glaspell,

Grace C. Sullivan,

Julia M. Hurley,

Mackenzie R. Deighen,

Akila S. Venkataramany,

Xiaokui Mo,

Joseph Stanek,

Anthony R. Miller,

Saranga Wijeratne,

Vincent Magrini,

Elaine R. Mardis,

Jerry R. Mendell,

Dawn S. Chandler,

Pin-Yi Wang

Publication year - 2022

Publication title -

science advances

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.928

H-Index - 146

ISSN - 2375-2548

DOI - 10.1126/sciadv.abm1890

Subject(s) - chimeric antigen receptor , cd19 , genetic enhancement , cancer research , immunotherapy , receptor , cell therapy , transgene , antigen , gene , computational biology , medicine , biology , immunology , microbiology and biotechnology , immune system , stem cell , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research